We also demonstrated that the synthetic cannabinoid WIN-55, a non-selective cannabinoid CB1 and CB2 receptor agonist, inhibits the proliferation of RCC primary (786-O) and metastatic (ACHN) cells through the activation of the CB2 receptor as determined by the Alamar Blue® cell viability assay. Here, CNR1 is linked to renal cell carcinoma.